-
-
-
-
-
-
C413955-100mgInformationCCT245737 (SRA737, PNT-737) is an orally activeCHK1inhibitor with The IC50 of 1.4 nM. It exhibits >:1,000-fold selectivity against CHK2 and CDK1.TargetsChk1 (Cell-free assay) 1.4 nMIn vitroCCT245737 is a potent inhibitor of recombinant
-
C413955-25mgInformationCCT245737 (SRA737, PNT-737) is an orally activeCHK1inhibitor with The IC50 of 1.4 nM. It exhibits >:1,000-fold selectivity against CHK2 and CDK1.TargetsChk1 (Cell-free assay) 1.4 nMIn vitroCCT245737 is a potent inhibitor of recombinant
-
C413955-5mgInformationCCT245737 (SRA737, PNT-737) is an orally activeCHK1inhibitor with The IC50 of 1.4 nM. It exhibits >:1,000-fold selectivity against CHK2 and CDK1.TargetsChk1 (Cell-free assay) 1.4 nMIn vitroCCT245737 is a potent inhibitor of recombinant
-
C413899-100mgInformationCCT251545 CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.TargetsCDK8 :
-
C413899-10mgInformationCCT251545 CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.TargetsCDK8 :
-
C413899-25mgInformationCCT251545 CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.TargetsCDK8 :
-
C413899-50mgInformationCCT251545 CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.TargetsCDK8 :